Nakagawa Masamune, Oda Yoshinao, Eguchi Takashi, Aishima Shin-Ichi, Yao Takashi, Hosoi Fumihito, Basaki Yuji, Ono Mayumi, Kuwano Michihiko, Tanaka Masao, Tsuneyoshi Masazumi
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Oncol Rep. 2007 Oct;18(4):769-74.
Histone deacetylase (HDAC) activity is one of the widely used and well-established mechanisms for regulation of various genes in cancer. To identify which subtype of class I HDACs are overexpressed in cancers, we analyzed the expression of class I HDAC isotypes composed of HDAC1, 2, 3 and 8 in several cell lines and human cancer tissues, including cancer of the stomach, esophagus, colon, prostate, breast, ovary, lung, pancreas and thyroid. The results showed that >75% of human cancer tissues and their corresponding non-cancerous epithelium showed high expression of these class I HDACs. However, the immunoreactivity of HDAC8 in both prostatic cancer tissue and non-cancerous prostate glands was lower than that in other cancer tissues. Furthermore, 5-40% of cancer tissues overexpressed class I HDACs, when compared with normal epithelium. The results suggest the potential usefulness of HDAC inhibitors for the treatment of a wide variety of human cancers.
组蛋白去乙酰化酶（HDAC）活性是癌症中广泛使用且已确立的各种基因调控机制之一。为了确定I类HDAC的哪种亚型在癌症中过表达，我们分析了由HDAC1、2、3和8组成的I类HDAC同种型在几种细胞系和人类癌症组织中的表达，这些组织包括胃癌、食管癌、结肠癌、前列腺癌、乳腺癌、卵巢癌、肺癌、胰腺癌和甲状腺癌。结果显示，超过75%的人类癌症组织及其相应的非癌上皮显示出这些I类HDAC的高表达。然而，HDAC8在前列腺癌组织和非癌前列腺腺中的免疫反应性低于其他癌症组织。此外，与正常上皮相比，5-40%的癌症组织过表达I类HDAC。结果表明HDAC抑制剂在治疗多种人类癌症方面具有潜在的应用价值。
